Upfront Payments Soar 187% in 5 Years: Chinese Innovative Drugs Go Global as Cross-Border Collaborations Deepen

For global buyers, the evolution of Chinese innovative drugs is no longer merely about “more choices” — it has become a matter of “higher standards.”

As a long-term supplier for overseas markets, DengYueMed has observed a clear shift: international partners are increasingly evaluating Chinese innovative drugs based on value rather than price.

The data from the first quarter of 2026 illustrates this transformation.

As of March 25, 2026, there were 49 outbound business development (BD) deals involving Chinese innovative drugs, with total upfront payments exceeding $3.3 billion and total deal values approaching $57 billion.

The scale of a single quarter has already surpassed the entire 2024 total and is nearly half of 2025’s full-year volume.

Even more noteworthy than the total number of deals is the structural change. Average upfront payments reached $184 million, setting a new historical high:

• Up ~59% compared with 2025
• Up 187% compared with 2022

Upfront payments in BD deals are a clear indicator of the risk that buyers are willing to take at the early stages of a project. The continuous increase reflects two key developments:

1. The success probability of Chinese innovative drugs is being reassessed.
2. Trust from multinational pharmaceutical companies is being released earlier.

This shift signifies that Chinese innovative drugs are moving from being a “supplementary option” to a “priority allocation” in global collaborations.

Reviewing deal structures from 2022 to 2025 reveals a clear pathway: early-stage assets and antibody drugs formed the core foundation of China’s global expansion.

Among the top upfront deals:

• Preclinical and early clinical assets consistently accounted for around 66%, peaking at 85%
• Antibody drugs (monoclonal, bispecific/multispecific antibodies, ADCs) maintained a 55–65% share

This structure demonstrates that China’s initial entry into global markets relied on two capabilities:

1. Efficiency in advancing early-stage R&D
2. Technical expertise in antibody engineering

As deals progressed, upfront payments and their proportion of total deal value gradually increased. From modest levels in 2022 to exceeding hundreds of millions in 2023, and further growth in 2024 and beyond, pricing trends have closely tracked capability validation.

Behind the rising prices is the accumulated capability of Chinese innovative drugs across multiple dimensions.

On the technical side, antibody innovation is evolving:

• ADC payloads are shifting from traditional toxins to newer mechanisms
• Bispecific/multispecific antibodies are increasingly designed to target both tumors and the immune microenvironment
• Novel structures and combination strategies are becoming more diverse

In terms of quantity and progress, Chinese companies occupy a significant position. Many enhanced antibody drugs in the global clinical pipeline are developed by Chinese firms, with Chinese assets representing roughly half or more of bispecific antibodies and ADCs.

More importantly, success rates are notable. Data show that Chinese companies achieve substantially higher overall success rates from early clinical stages to approval compared with Western counterparts. This difference directly alters multinational pharma companies’ risk assessment.

When both innovation quality and translational ability are verified, Chinese assets are no longer merely a “cost advantage” but become “high-value, high-certainty” choices.

In 2026, outbound BD began to take on a new form. Deals are no longer limited to single-asset licensing but increasingly involve more systematic collaborations.

Among high-value deals, clear trends include:

• Increase in multi-project or platform-level collaborations
• Greater binding at early R&D stages
• Longer collaboration cycles, covering discovery to clinical validation

This model shows that multinational companies are not just interested in a single asset but in the sustained innovative capability of Chinese companies, including technology platforms, R&D systems, and execution efficiency.

Such a shift also explains the sustained rise in upfront payments — pricing now reflects the long-term value of the collaboration, not just a single project.

Beyond technical progress, disease areas are also evolving.

Previously, oncology dominated outbound BD deals, accounting for nearly 95% at peak. In recent years, this share has gradually declined, falling below 50% since 2025.

New growth areas mainly focus on:

• Cardiovascular and metabolic diseases
• Autoimmune diseases

This aligns with global pharmaceutical trends, shifting from high-risk, high-reward oncology to chronic diseases with longer-term, stable returns.

Sustained interest in metabolic drugs and long-term treatment demand for autoimmune diseases are driving multinational pharma to increase their engagement.

Two additional trends are noteworthy:

1. Mature antibody technologies exploring non-oncology indications
2. Emerging technologies continuing to enter oncology

This bidirectional extension expands the application boundaries of Chinese innovative drugs.

Taken together, these developments indicate that the increase in upfront payments is not an isolated phenomenon but a reflection of the overall elevation of Chinese innovative drugs’ global position.

On one hand, Chinese companies have strong supply capabilities across multiple subfields. On the other, high-quality assets are scarce on a global scale. This forces multinational companies to accept higher pricing in competitive bids.

Through this process, Chinese innovative drugs are gradually shifting from global market participants to influential players capable of shaping deal structures and pricing strategies.

For overseas buyers and partners, the trend is already impacting operations.

First, pricing structures are rising. Chinese innovative drugs remain cost-effective but are no longer a low-cost alternative, instead offering value comparable to global innovative therapies.

Second, access windows for high-quality assets have moved earlier, with many projects securing partnerships at the early stage.

Finally, collaboration thresholds are increasing, extending beyond simple procurement to comprehensive requirements in compliance, channel management, and execution capabilities.

These shifts mean that international buyers must engage earlier and collaborate more deeply to access premium resources.

The globalization of Chinese innovative drugs is entering a critical phase, moving from expansion in scale to improvement in quality. The continuous rise in upfront payments not only reflects pricing changes but also signals global recognition of China’s innovation capabilities.

In this process, companies like HongKong DengYue Medicine are evolving from traditional distributors to global connectors of innovation, helping international clients efficiently access China’s innovative drug ecosystem.

As collaboration models and pricing frameworks continue to evolve, the influence of Chinese innovative drugs in the global pharmaceutical industry is entering a new era.